A UK government-backed startup aims to accelerate drug discovery by training AI models on computer-generated biochemical data. The approach could shorten the lengthy process of developing new medicines.
Potential Sciences is betting that simulated data can replace some physical laboratory work. The company says this method may reduce the time and cost of early-stage drug research.
Traditional drug discovery relies on extensive lab testing, which can take years. Computer-generated datasets offer a faster alternative for training AI systems.
The startup’s strategy focuses on creating synthetic biochemical information. These datasets help AI models learn patterns that might predict how potential drugs behave.
AI has already shown promise in identifying drug candidates. Training on simulated data could further streamline that search by removing bottlenecks tied to physical experiments.
The approach does not eliminate laboratory testing entirely. It aims to prioritize the most promising compounds before they reach the lab, saving resources.
Investors and researchers are watching whether computer-generated data can match the reliability of real-world experiments. Success would mark a significant shift in how new drugs are discovered.
